CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 24 enrolled
Drug / intervention
Placebo +3 moredrug
Likely dose
Enalapril 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00666848
NCT00666848Phase 4Completed
CompareCT.gov

Effect of Sitagliptin on the Blood Pressure Response to ACE Inhibition in the Metabolic Syndrome

Vanderbilt University·interventional·Posted Apr 25, 2008·Updated May 11, 2012

In Brief

A Phase 4 clinical trial evaluating Placebo, Enalapril 5mg, and 2 other interventions for Metabolic Syndrome and Hypertension. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study will measure the effect of the anti-diabetic agent sitagliptin on blood pressure in individuals with the metabolic syndrome. We will also measure the effect of sitagliptin on blood pressure in people already taking a blood pressure medication called an ACE inhibitor.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome, Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 25, 2008
Enrollment StartMar 1, 2008
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 18.2 years ago

Interventions

Placebodrug

Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d

Enalapril 5mgdrug

Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d

Enalapril 10mgdrug

Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d

Sitagliptindrug

Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.